FDA Approves Luspatercept-aamt for Anemia In Adults Wit...
(FDA.gov) Apr 6, 2020 - On April 3, 2020, the Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corporation) for the ...
Immunomedics Announces ASCENT Study to be Stopped for C...
(Immunomedics) Apr 6, 2020 - Decision based on recommendation from DSMC following study data review. Sacituzumab govitecan has the potential ...
Merck Receives Priority Review from FDA for Second Appl...
(Merck) Apr 7, 2020 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FD...
Karyopharm to Evaluate Low Dose Selinexor as a Potentia...
(Karyopharm) Apr 7, 2020 - Karyopharm Therapeutics Inc. today announced plans to initiate a global randomized clinical trial for low dose oral...
Bradley McGregor, MD, on impressions of phase I/II study of oral HIF-2 α inhibitor MK-6482 in patients with adv...
Tian Zhang, MD, on the follow up study investigating nivolumab + ipilimumab in 1st line RCC patients
New Telehealth Policies Ensuring Cancer Patients Aren&r...Apr 07, 2020
by Ted Okon
I don’t have to tell anyone that the novel coronavirus has caused an unprecedented global crisis. However, with attention rightfully so on COVID-...
Dean's Digest - ASCO GU 2020Feb 19, 2020
Major themes which emerged from ASCO GU 2020 included a plethora of studies utilizing various permutations of targeted therapies along with immunotherapy and/or c...
Dean's Digest - ASCO GI 2020Jan 28, 2020
ASCO GI 2020 was held in San Francisco January 23-25. Numerous studies involving Phase 1/2 evaluations of new drugs in gastrointestinal (GI) malignancies were rep...
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.Learn More
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.Learn More
[by phone or online via webcast]
[Virtual Group Meeting]
New Orleans, LA
New York, NY
Miami Beach, FL
National Harbor, MD
San Diego, CA
Karuizawa, Nagano, Japan
|Date||Company and Product|
UroGen Pharma Ltd. ,
Blueprint Medicines ,